Year All20232022202120202019201820172016201520142013201220112009 Jun 01, 2023 REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference May 23, 2023 REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome May 22, 2023 REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023 May 16, 2023 REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio May 08, 2023 REGENXBIO to Participate in Upcoming Investor Conferences May 03, 2023 REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights May 02, 2023 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 23, 2023 REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome
May 16, 2023 REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio
May 03, 2023 REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
May 02, 2023 REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting
